The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program.
Masafumi OnoKuniaki TakahashiChao GaoHideyuki KawashimaXinlei WuHironori HaraRutao WangJoanna J WykrzykowskaJan J PiekFaisal SharifPatrick W SerruysWilliam WijnsYoshinobu OnumaPublished in: Future cardiology (2020)
Drug-eluting stents (DES) have been developed over recent decades and the implantation of DES is the standard of care in contemporary percutaneous coronary intervention for patients with coronary artery disease. The MiStent sirolimus-eluting stent has several unique features; ultra-thin (64 μm) struts, a bioresorbable polymer and a controlled drug release from microcrystalline sirolimus as a reservoir embedded in the vessel wall. Results of recent clinical trials demonstrated the potential performance of this state-of-the-art DES. In the present review, we provide an overview of the development of DES, in particular the design and performance of the novel MiStent sirolimus-eluting stent from technological and clinical points of view and discuss the potentials of this new type of DES.
Keyphrases
- percutaneous coronary intervention
- clinical trial
- coronary artery disease
- quality improvement
- healthcare
- acute coronary syndrome
- coronary artery
- palliative care
- acute myocardial infarction
- st segment elevation myocardial infarction
- coronary artery bypass grafting
- high resolution
- heart failure
- risk assessment
- adverse drug
- antiplatelet therapy
- pain management
- open label
- human health
- transcatheter aortic valve replacement
- double blind